There is no cure for Crohn’s disease (hereafter referred to as CD). The question about the prognosis of the disease is actually mainly concerned with how the patient will fare in comparison to a disease-free population of the same age and sex for a considerable period of time in the future. There are significant differences between the course of disease in each CD patient. Foreign studies have found that in a given observation year, approximately 55% of patients are in clinical remission, 15% are in mild activity, and 30% are suffering from severe active disease. Thus, questions about disease prognosis must be obtained from a real population-based cohort of patients that are representative of all disease types (various levels of activity, extent of lesions) and not through a particular hospital population or a particular surgical center case (which are usually sicker and do not reflect the overall patient population). In the 1960s and 1970s, Truelove and Pena completed the first epidemiological study of patients with inflammatory bowel disease. They divided patients into “new cases” (diagnosed and treated at the same regional hospital) and “selected cases” (patients selected for treatment at a higher level of care). The authors found that new cases had a higher survival rate than selected cases at 10 years. Subsequent population studies showed some variation, with results ranging from no effect on mortality to a mild increase. Further analysis revealed that the observed increased mortality was related to the extent of the lesion, the duration of the disease, and the female nature of CD. In addition to being related to the characteristics of CD itself, some patients died from other gastrointestinal, liver, and biliary tract diseases as well as lung tumors. About 30% of all patients who died were related to CD disease itself. The causes of death in this group of patients are divided into two categories: one occurs in the early stages of the disease and is related to clinical or surgical complications; the second occurs in the late stages of the disease mainly due to intestinal tumors. To date, it is inconclusive whether the application of immunosuppressive/biological agents can modify the overall mortality rate and or the etiology of death in patients with CD. These treatments may reduce postoperative mortality by reducing surgical rates, but should be weighed against the possible increased risk of death due to adverse effects of treatment.